HomeCVAC • NASDAQ
add
CureVac BV
$3.26
Makalipas ang Oras ng Trabaho:(2.15%)-0.070
$3.19
Sarado: Hul 12, 7:47:42 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$3.27
Sakop ng araw
$3.17 - $3.39
Sakop ng taon
$2.22 - $10.55
Market cap
731.24M USD
Average na Volume
1.45M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga Financial
Income Statement
Kita
Net na kita
| (EUR) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 12.37M | 73.56% |
Gastos sa pagpapatakbo | 47.77M | -1.92% |
Net na kita | -70.55M | -22.87% |
Net profit margin | -570.22 | 29.20% |
Kita sa bawat share | -0.31 | -14.81% |
EBITDA | -72.22M | -28.15% |
Aktuwal na % ng binabayarang buwis | -0.95% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (EUR) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 300.15M | -51.39% |
Kabuuang asset | 690.43M | -29.09% |
Kabuuang sagutin | 243.52M | -6.44% |
Kabuuang equity | 446.91M | — |
Natitirang share | 224.31M | — |
Presyo para makapag-book | 1.64 | — |
Return on assets | -26.07% | — |
Return on capital | -36.84% | — |
Cash Flow
Net change in cash
| (EUR) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -70.55M | -22.87% |
Cash mula sa mga operasyon | -96.55M | 3.04% |
Cash mula sa pag-invest | -5.09M | 61.34% |
Cash mula sa financing | -1.12M | -100.48% |
Net change in cash | -102.30M | -184.04% |
Malayang cash flow | -68.47M | 25.88% |
Tungkol
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Itinatag
2000
Website
Mga Empleyado
1,086
